{"url":"https://lda.senate.gov/api/v1/filings/f402b48d-e809-42f2-a6ff-fa3ac5c268ba/","filing_uuid":"f402b48d-e809-42f2-a6ff-fa3ac5c268ba","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2013,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/f402b48d-e809-42f2-a6ff-fa3ac5c268ba/print/","filing_document_content_type":"text/html","income":null,"expenses":"78690.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Mark Cooke, Sr. Director Government Affairs","dt_posted":"2013-07-22T18:09:13.660000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1 Park Place, #450","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"ANNAPOLIS","registrant_state":"MD","registrant_zip":"21401","registrant":{"id":285370,"url":"https://lda.senate.gov/api/v1/registrants/285370/","house_registrant_id":36974,"name":"PHARMATHENE, INC","description":"Biotechnology research, development and manufacturing. Biodefense vaccines/therapeutics","address_1":"1 Park Place, #450","address_2":null,"address_3":null,"address_4":null,"city":"ANNAPOLIS","state":"MD","state_display":"Maryland","zip":"21401","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"FRANCESCA COOK","contact_telephone":"+1 410-269-2515","dt_updated":"2022-04-06T16:08:24.318364-04:00"},"client":{"id":176005,"url":"https://lda.senate.gov/api/v1/clients/176005/","client_id":12,"name":"PHARMATHENE, INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2009-01-21"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocacy for funding of Bioshield Special Reserve Fund (SRF) as authorized in the  Pandemic and All-Hazards Preparedness Reauthorization Act 2013.  Advocacy for funding of BARDA at HHS. Education of House and Senate staff on anthrax recombinant protective antigen vaccine and recombinant butyrlcholinesterase as an organophosphate bioscavneger for chemical nerve agent prophylaxis.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":44682,"prefix":"mr","prefix_display":"MR.","first_name":"MARK","nickname":null,"middle_name":"EDWARD","last_name":"COOKE","suffix":null,"suffix_display":null},"covered_position":"Sr. Director Government Affairs","new":false},{"lobbyist":{"id":17384,"prefix":null,"prefix_display":null,"first_name":"FRANCESCA","nickname":null,"middle_name":null,"last_name":"COOK","suffix":null,"suffix_display":null},"covered_position":"Sr. VP Policy and Government Affairs","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}